Literature DB >> 18942670

The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis.

Matthew C Cheung1, Kevin R Imrie, Jessica Friedlich, Rena Buckstein, Nina Lathia, Nicole Mittmann.   

Abstract

INTRODUCTION: Although much is known about the efficacy, toxicity, and direct costs of treatment for follicular lymphoma (FL), there is no data assessing the impact of this diagnosis on the work productivity of affected individuals.
METHODS: We conducted a cross-sectional survey study of consecutive patients attending a malignant haematology clinic at a large multi-disciplinary cancer centre. Patients with a diagnosis of FL or other indolent non-Hodgkin's lymphoma completed questionnaires assessing health status, work productivity, and activity impairment.
RESULTS: Eighty-four patients completed the survey study (95% response). Patients who continued to work reported a minimal impact on their work productivity (10%+/-standard deviation SD 20; 0%=no effect and 100%=complete impairment of activity) and on their daily activities (13%+/-SD 25) attributable to their cancer. Prior to lymphoma diagnosis, over 71% of patients were working while 14% were retired. At the time of survey administration, only 41% of patients were still able to work with a significant proportion of patients having transitioned to retirement (36%), sick leave (10%), or unemployment (4%). On multivariate analysis, significant activity impairment (daily activity impairment>50%) was predicted by poor self-rated health status (OR 32.1; 95% CI: 5.9-174.2; p<0.0001) and active chemotherapy treatment (OR 14.5; 95% CI: 0.91-230.9; p=0.059).
CONCLUSIONS: Although few patients with indolent lymphoma identified significant impairment in productivity, many were unable to continue employment following diagnosis, needed to miss days from work, or imposed a significant burden on caregivers. The greatest impact on activity is apparent in patients who rate their health status as poor and in those who are currently receiving systemic therapy. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 18942670     DOI: 10.1002/pon.1404

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  5 in total

1.  Returning to work after treatment for haematological cancer: findings from Australia.

Authors:  Pam D McGrath; Barbara Hartigan; Hamish Holewa; Maryanne Skarparis
Journal:  Support Care Cancer       Date:  2011-10-28       Impact factor: 3.603

2.  Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.

Authors:  Mark S Walker; Edward J Stepanski; Carolina Reyes; Sacha Satram-Hoang; Arthur C Houts; Lee S Schwartzberg
Journal:  Ther Adv Hematol       Date:  2011-06

3.  Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.

Authors:  Firas Badin; John Hayslip
Journal:  Clinicoecon Outcomes Res       Date:  2010-04-07

4.  The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma.

Authors:  Joanna M Davies; Thomas R Osborne; Polly M Edmonds; Steve A Schey; Steve Devereux; Irene J Higginson; Christina Ramsenthaler
Journal:  Eur J Haematol       Date:  2017-03-09       Impact factor: 2.997

5.  Lifetime Costs for Treated Follicular Lymphoma Patients in the US.

Authors:  Caitlin Eichten; Qiufei Ma; Thomas E Delea; May Hagiwara; Roberto Ramos; Şerban R Iorga; Jie Zhang; Richard T Maziarz
Journal:  Pharmacoeconomics       Date:  2021-07-17       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.